Delcath Systems (DCTH) reports inducement grants

Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to six individuals whose employment commenced in January and February of 2025.

The grants resulted in the right to purchase 264,000 shares of the Company’s common stock and are subject to the terms and conditions of the Company’s 2023 Inducement Plan (“Plan”). The options were granted on February 28, 2025, the date the Compensation Committee approved the stock option included within the equity inducements and are subject to an exercise price equal to $14.17, the closing price of Delcath’s common stock on February 28, 2025. One-third of the options will vest on the first anniversary of the grant date with the remaining two-thirds of the options vesting in equal monthly installments over the following twenty-four months. The options have a ten-year term and the vesting of the options are subject to the employee’s continued employment with Delcath on each vesting date.

The above-described awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and granted pursuant to the terms of the Plan.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Tianci International updates Zimbabwe gold and chromium project progress
• Robo.ai Inc (AIIO) files for 22.34M share offering by selling stockholders